Summary
Global Markets Direct’s, ‘Boehringer Ingelheim GmbH - Product Pipeline Review - 2016’, provides an overview of the Boehringer Ingelheim GmbH’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Boehringer Ingelheim GmbH, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Boehringer Ingelheim GmbH
- The report provides overview of Boehringer Ingelheim GmbH including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Boehringer Ingelheim GmbH’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Boehringer Ingelheim GmbH’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Boehringer Ingelheim GmbH’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Boehringer Ingelheim GmbH
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Boehringer Ingelheim GmbH’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Boehringer Ingelheim GmbH Snapshot 6
Boehringer Ingelheim GmbH Overview 6
Key Information 6
Key Facts 6
Boehringer Ingelheim GmbH - Research and Development Overview 7
Key Therapeutic Areas 7
Boehringer Ingelheim GmbH - Pipeline Review 14
Pipeline Products by Stage of Development 14
Pipeline Products - Monotherapy 15
Pipeline Products - Combination Treatment Modalities 16
Pipeline Products - Partnered Products 17
Pipeline Products - Out-Licensed Products 19
Boehringer Ingelheim GmbH - Pipeline Products Glance 21
Boehringer Ingelheim GmbH - Late Stage Pipeline Products 21
Boehringer Ingelheim GmbH - Clinical Stage Pipeline Products 23
Boehringer Ingelheim GmbH - Early Stage Pipeline Products 26
Boehringer Ingelheim GmbH - Drug Profiles 29
(empagliflozin + linagliptin) 29
(linagliptin + metformin hydrochloride ER) 30
(olodaterol hydrochloride + tiotropium bromide) 31
idarucizumab 34
(empagliflozin + metformin hydrochloride XR) 35
adalimumab biosimilar 36
afatinib dimaleate 37
bevacizumab biosimilar 42
empagliflozin 43
nintedanib 45
risankizumab 50
rituximab biosimilar 52
volasertib trihydrochloride 53
BI-1026706 56
BI-1361849 57
BI-144807 58
BI-409306 59
FX-125L 61
HM-61713 63
BI-836826 64
BI-836845 65
BI-836858 67
BI-1005273 68
BI-1060469 69
BI-113608 70
BI-416970 71
BI-425809 72
BI-443651 73
BI-655064 74
BI-655088 75
BI-655130 76
BI-685509 77
BI-836880 78
BI-836909 79
BI-853520 80
BI-860585 81
BI-894999 82
PXS-4728A 83
Small Molecule for Oncology 84
AR-116082 85
BI-113823 86
BI-1467335 87
BI-186908 88
BI-207524 Follow-Up 89
BI-703704 90
BI-882370 91
CNX-012 92
CNX-012570 93
linagliptin 94
Monoclonal Antibody for Ophthalmology 95
olcegepant 96
Small Molecule 2 for Oncology 98
Small Molecule 2 to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis 99
Small Molecule 3 for Oncology 100
Small Molecule for Respiratory Diseases 101
Small Molecule to Agonize Glucocorticoid Receptor for Inflammation 102
Small Molecule to Agonize Glucocorticoid Receptor for Rheumatoid Arthritis 103
Small Molecule to Inhibit PI4KIII beta for Rhinovirus Infection 104
Small Molecules for Respiratory Disorders 105
Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection 106
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy 107
Synthetic Peptide for CardioMetabolic Disease 108
Antibody for Oncology 109
BI-665915 110
Small Molecule for HIV 111
Small Molecule for HIV-1 Infection 112
Small Molecule to Agonize Glucocorticoid Receptor 113
Small Molecule to Agonize ROR-Gamma for Autoimmune and Allergic Disorders 114
Small Molecules for Oncology 115
Small Molecules for Schizophrenia 116
Small Molecules for Undisclosed Indication 117
Small Molecules to Inhibit K-Ras for Oncology 118
Small Molecules to Inhibit Kinases for Oncology 119
Synthetic Peptide to Agonize Glucagon and GLP-1 for Metabolic Disorders 120
Boehringer Ingelheim GmbH - Pipeline Analysis 121
Boehringer Ingelheim GmbH - Pipeline Products by Target 121
Boehringer Ingelheim GmbH - Pipeline Products by Route of Administration 125
Boehringer Ingelheim GmbH - Pipeline Products by Molecule Type 126
Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action 127
Boehringer Ingelheim GmbH - Recent Pipeline Updates 130
Boehringer Ingelheim GmbH - Dormant Projects 166
Boehringer Ingelheim GmbH - Discontinued Pipeline Products 169
Discontinued Pipeline Product Profiles 169
Boehringer Ingelheim GmbH - Company Statement 172
Boehringer Ingelheim GmbH - Locations And Subsidiaries 174
Head Office 174
Other Locations & Subsidiaries 174
Appendix 179
Methodology 179
Coverage 179
Secondary Research 179
Primary Research 179
Expert Panel Validation 179
Contact Us 179
Disclaimer 180
List of Tables
Boehringer Ingelheim GmbH, Key Information 12
Boehringer Ingelheim GmbH, Key Facts 12
Boehringer Ingelheim GmbH - Pipeline by Indication, 2016 14
Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2016 20
Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2016 21
Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2016 22
Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2016 23
Boehringer Ingelheim GmbH - Partnered Products/ Combination Treatment Modalities, 2016 24
Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2016 25
Boehringer Ingelheim GmbH - Out-Licensed Products/ Combination Treatment Modalities, 2016 26
Boehringer Ingelheim GmbH - Pre-Registration, 2016 27
Boehringer Ingelheim GmbH - Phase III, 2016 28
Boehringer Ingelheim GmbH - Phase II, 2016 29
Boehringer Ingelheim GmbH - Phase I, 2016 30
Boehringer Ingelheim GmbH - Preclinical, 2016 32
Boehringer Ingelheim GmbH - Discovery, 2016 34
Boehringer Ingelheim GmbH - Pipeline by Target, 2016 127
Boehringer Ingelheim GmbH - Pipeline by Route of Administration, 2016 131
Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2016 132
Boehringer Ingelheim GmbH - Pipeline Products by Mechanism of Action, 2016 133
Boehringer Ingelheim GmbH - Recent Pipeline Updates, 2016 136
Boehringer Ingelheim GmbH - Dormant Developmental Projects,2016 172
Boehringer Ingelheim GmbH - Discontinued Pipeline Products, 2016 175
Boehringer Ingelheim GmbH, Subsidiaries 180
List of Figures
Boehringer Ingelheim GmbH - Pipeline by Top 10 Indication, 2016 14
Boehringer Ingelheim GmbH - Pipeline by Stage of Development, 2016 20
Boehringer Ingelheim GmbH - Monotherapy Products in Pipeline, 2016 21
Boehringer Ingelheim GmbH - Combination Treatment Modalities in Pipeline, 2016 22
Boehringer Ingelheim GmbH - Partnered Products in Pipeline, 2016 23
Boehringer Ingelheim GmbH - Out-Licensed Products in Pipeline, 2016 25
Boehringer Ingelheim GmbH - Pipeline by Top 10 Target, 2016 127
Boehringer Ingelheim GmbH - Pipeline by Route of Administration, 2016 131
Boehringer Ingelheim GmbH - Pipeline by Molecule Type, 2016 132
Boehringer Ingelheim GmbH - Pipeline Products by Top 10 Mechanism of Action, 2016 133
